Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations

Daniel Halstuch, Yaara Ber, David Margel

Research output: Contribution to journalComment/debate

Abstract

Male carriers of BRCA mutations are at higher risk of developing prostate cancer. Many issues are still unanswered and are currently being studied, including differences between BRCA1 and BRCA2, screening and specific protocols, the role of active surveillance, and the choice of definitive treatment.

Original languageEnglish
Pages (from-to)212-214
Number of pages3
JournalEuropean Urology Focus
Volume6
Issue number2
DOIs
StatePublished - 15 Mar 2020

Fingerprint

Dive into the research topics of 'Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations'. Together they form a unique fingerprint.

Cite this